CN104374911B - A kind of detection by quantitative rheumatoid factor, the detection kit of antistreptolysin O (ASO) - Google Patents

A kind of detection by quantitative rheumatoid factor, the detection kit of antistreptolysin O (ASO) Download PDF

Info

Publication number
CN104374911B
CN104374911B CN201410738142.8A CN201410738142A CN104374911B CN 104374911 B CN104374911 B CN 104374911B CN 201410738142 A CN201410738142 A CN 201410738142A CN 104374911 B CN104374911 B CN 104374911B
Authority
CN
China
Prior art keywords
detection
aso
antistreptolysin
rheumatoid factor
test paper
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410738142.8A
Other languages
Chinese (zh)
Other versions
CN104374911A (en
Inventor
段继凤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhongyuan Huiji Biotechnology Co Ltd
Original Assignee
CHONGQING QIANDE BIOTECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHONGQING QIANDE BIOTECHNOLOGY Co Ltd filed Critical CHONGQING QIANDE BIOTECHNOLOGY Co Ltd
Priority to CN201410738142.8A priority Critical patent/CN104374911B/en
Publication of CN104374911A publication Critical patent/CN104374911A/en
Application granted granted Critical
Publication of CN104374911B publication Critical patent/CN104374911B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/101Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

The present invention relates to field of biological detection, particularly relate to detection kit of a kind of detection by quantitative rheumatoid factor, antistreptolysin O (ASO) and its production and use.The present invention provides a kind of detection kit, including the most independent rheumatoid factor Test paper card and antistreptolysin O (ASO) Test paper card, described rheumatoid factor Test paper card and antistreptolysin O (ASO) Test paper card the most each include base plate and be positioned at backplate surface start, from sample-adding end, the sample pad, fluorescent marker pad, nitrocellulose filter and the adsorptive pads that are arranged in order.Rheumatoid factor in rheumatism three, antistreptolysin O (ASO) are detected by detection kit provided by the present invention first by fluorescent micro-ball immune chromatography technology simultaneously, the content of rheumatoid factor in sample, antistreptolysin O (ASO) just can be detected by being once loaded operation, simplify operating process, have susceptiveness and specificity, quick and precisely assessment rheumatoid arthritis clinical symptoms concurrently.

Description

A kind of detection by quantitative rheumatoid factor, the detection kit of antistreptolysin O (ASO)
Technical field
The present invention relates to field of biological detection, particularly relate to a kind of detection by quantitative rheumatoid factor, antistreptolysin O (ASO) Detection kit and its production and use.
Background technology
Rheumatoid factor (rheumatoid factor, RF) can be divided into IgM, IgA, IgG, IgD, IgE five type (note: facing It is four types described in bed internal medicine, there is no IgD type;But it is 5 types described in the laboratory diagnosis), it is rheumatoid arthritis blood For a class autoantibody of epitope in IgG FC fragment in Qing, rheumatoid factor positive patient is more with joint appearance Existing, such as subcutaneous nodule and vasculitis etc..IgM type RF positive rate is 60%-78%.
After body infects A group B streptococcus because of pharyngitis, tonsillitis, scarlet fever, erysipelas, pyoderma, rheumatic fever etc., can produce Streptolysin O antibody, i.e. " Anti-Streptolysin O (ASO) ".
Summary of the invention
The shortcoming of prior art in view of the above, it is an object of the invention to provide a kind of detection by quantitative rheumatoid factor, anti-chain Detection kit of pneumoniae pneumolysin O and its production and use, is used for solving the problems of the prior art.
For achieving the above object and other relevant purposes, the present invention provides a kind of detection by quantitative rheumatoid factor (RF), anti-hammer The detection kit of bacterium hemolysin O (ASO), including the most independent rheumatoid factor Test paper card and streptococcus haemolysis Element O Test paper card, described rheumatoid factor Test paper card and antistreptolysin O (ASO) Test paper card the most each include the end Plate and be positioned at the sample pad starting to be arranged in order from sample-adding end of backplate surface, fluorescent marker pad, nitrocellulose filter And adsorptive pads, the fluorescent marker pad of described rheumatoid factor Test paper card comprises people degeneration IgG, described anti-hammer Hammer bacteriolysin O (SLO), described each celluloid is comprised on the fluorescent marker pad of bacterium hemolysin O Test paper card Being coated with detection line and nature controlling line on film, hammer bacteriolysin O and people degeneration IgG on described fluorescent marker pad use glimmering Light microsphere labelling.
Preferably, so that test kit has more preferably sensitivity and color developing effect, heretofore described fluorescent marker knot Close pad also pre-treatment buffer used in pretreatment, pretreatment and include following component: stachyose, Alumen, fructose two Sodium phosphate, sodium hexameta phosphate and glycine, and stachyose, Alumen, Fructose Diphosphate sodium, sodium hexameta phosphate, glycine is total Concentration is 3.5-7.5g/L, and the pH value of buffer is 7.2-7.6.
Preferably, each component concentration in buffer is:
The solvent of described pre-treatment buffer is water.
Concretely comprising the following steps of described pretreatment: fluorescent marker pad soaks in pretreatment fluid 1.5-2.5h, and taking-up is put in 36-38 DEG C of drying.
Described pre-treatment buffer can use the various conventional pH adjusting agent in this area to carry out the regulation of pH value.
Preferably, described base plate is PVC base plate.
Preferably, on described nitrocellulose filter, detection line is positioned at side close to sample-adding end, and nature controlling line is positioned at from sample-adding end relatively Remote side.
Preferably, the detection line of described rheumatoid factor Test paper card is coated with people degeneration IgG..
Preferably, the detection line of described antistreptolysin O (ASO) Test paper card is coated with streptolysin O.
Preferably, nature controlling line is coated sheep anti-mouse antibody.
Preferably, also include getting stuck, described in get stuck and include that back card and upper cover, described back card are provided with two parallel test card draw-in grooves, Described test card is embedded in described test card draw-in groove respectively, described on be covered with two testing windows and two wells, said two Match with detection line and the position of nature controlling line of two test cards respectively in the position of testing window, the position of said two well with Match in the position of the sample pad of two test cards.
Get stuck described in it is furthermore preferred that and get stuck for plastics.
It is furthermore preferred that be additionally provided with the translot connecting two wells between said two well.
Preferably, described detection kit detects rheumatoid factor, the content of antistreptolysin O (ASO) for simultaneous quantitative.
Detection by quantitative rheumatoid factor provided by the present invention, the detection kit of antistreptolysin O (ASO) use double when detection Antigen sandwich immunochromatographic method, supporting immune quantitative analytical tool uses.Immunoassay instrument passes through acquisition testing line (T) and matter Control line (C) band fluorescence signal, calculates T/C signal value.First various criterion product are added drop-wise on test card before using, analyze Calibration curve (T/C signal value and the relation of standard substance actual value) is set up in process, then by the T/C value obtained when detecting sample and mark Directrix curve compares, and can obtain the rheumatoid factor in detection sample, the content of antistreptolysin O (ASO).
Second aspect present invention provides the preparation of the detection kit of described detection by quantitative rheumatoid factor, antistreptolysin O (ASO) Method, comprises the steps:
1) SLO and people's degeneration IgG solution with fluorescent microsphere labelling spray antistreptolysin O (ASO), rheumatoid factor respectively Fluorescent marker pad;
2) on the detection line and nature controlling line of antistreptolysin O (ASO) nitrocellulose filter, SLO and sheep anti-mouse antibody are sprayed respectively, The detection line and nature controlling line of rheumatoid factor nitrocellulose filter spray people degeneration IgG and sheep anti-mouse antibody respectively;
3) nitrocellulose filter prepared by the fluorescent marker pad two set sample pad, steps 1 prepared, step 2, water suction Pad is pasted onto on respective base plate successively, and cutting prepares Test paper card;Finally being snapped fits into by Test paper gets stuck prepares detection examination Agent box.
Preferably, so that test kit has more preferably sensitivity and color developing effect, heretofore described fluorescent marker knot Close pad also pre-treatment buffer used in pretreatment, pretreatment and include following component: stachyose, Alumen, fructose two Sodium phosphate, sodium hexameta phosphate and glycine, and stachyose, Alumen, Fructose Diphosphate sodium, sodium hexameta phosphate, glycine is total Concentration is 3.5-7.5g/L, and the pH value of buffer is 7.2-7.6.
Preferably, each component concentration in buffer is:
The solvent of described pre-treatment buffer is water.
Concretely comprising the following steps of described pretreatment: fluorescent marker pad soaks in pretreatment fluid 2h, takes out and is put in 37 DEG C Dry.
Third aspect present invention provide described detection by quantitative rheumatoid factor, antistreptolysin O (ASO) detection kit at class wind The wet factor, the purposes of antistreptolysin O (ASO) detection field.
Detection by quantitative rheumatoid factor provided by the present invention, antistreptolysin O (ASO) detection kit first by rheumatism three In rheumatoid factor, antistreptolysin O (ASO) detected, by once adding by fluorescent micro-ball immune chromatography technology simultaneously Sample operation just can detect the content of rheumatoid factor in sample, antistreptolysin O (ASO), simplifies operating process, has spirit concurrently Quick property and specificity, quick and precisely assessment rheumatoid arthritis clinical symptoms.Additionally, described detection kit has operation quickly The advantages such as easy, result is accurate, economic and practical, little by the serious blood fat of serum (or blood plasma), haemolysis interference, when serum (or Blood plasma) hemoglobin≤600mg/L, triglyceride≤100mg/dL time, bilirubin≤20mg/dL, the impact on accuracy Variation < 10%.
Detailed description of the invention
Below by way of specific instantiation, embodiments of the present invention being described, those skilled in the art can be by disclosed by this specification Content understand other advantages and effect of the present invention easily.The present invention can also be added by the most different detailed description of the invention To implement or application, the every details in this specification can also be based on different viewpoints and application, in the essence without departing from the present invention Various modification or change is carried out under god.
Before further describing the specific embodiment of the invention, it should be appreciated that protection scope of the present invention is not limited to following specific Specific embodiments;It is also understood that the term used in the embodiment of the present invention is to describe specific specific embodiments, Rather than in order to limit the scope of the invention;In description of the invention and claims, unless literary composition additionally clearly refers to Going out, singulative " ", " one " and " this " include plural form.
When embodiment provides numerical range, it should be appreciated that unless the present invention is otherwise noted, two end points of each numerical range with And any one numerical value all can be selected between two end points.Unless otherwise defined, all technology used in the present invention and section are academic The same meaning that language and those skilled in the art of the present technique are generally understood that.In addition to the concrete grammar used in embodiment, equipment, material, According to those skilled in the art's grasp to prior art and the record of the present invention, it is also possible to use and the embodiment of the present invention Described in method, any method, equipment and the material of the similar or equivalent prior art of equipment, material realize the present invention.
Unless otherwise indicated, the experimental technique that disclosed in this invention, detection method, preparation method all use the art normal Rule molecular biology, biochemistry, chromatin Structure and analysis, analytical chemistry, cell cultivate, recombinant DNA technology and The routine techniques of association area.These technology have improved explanation in existing document, specifically can be found in Sambrook etc. MOLECULAR CLONING:A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989and Third edition, 2001;Ausubel etc., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley&Sons, New York, 1987and periodic updates;the series METHODS IN ENZYMOLOGY, Academic Press, San Diego;Wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998;METHODS IN ENZYMOLOGY, Vol.304, Chromatin (P.M.Wassarman and A.P.Wolffe, eds.), Academic Press, San Diego, 1999;With METHODS IN MOLECULAR BIOLOGY, Vol.119, Chromatin Protocols (P.B.Becker, ed.) Humana Press, Totowa, 1999 etc..
Embodiment 1
The preparation of test card of the present invention:
1) using pre-treatment buffer that fluorescent marker pad is carried out pretreatment, pre-treatment buffer is: stachyose 2g/L, Alumen 0.5g/L, Fructose Diphosphate sodium 1.5g/L, sodium hexameta phosphate 0.3g/L, the aqueous solution of glycine 1.88g/L, pH=7.4, Concretely comprising the following steps of pretreatment: fluorescent marker pad soaks in pretreatment fluid 2h, takes out and is put in 37 DEG C of drying;With SLO and people's degeneration IgG buffer solution of appropriate fluorescent microsphere labelling spray pretreated fluorescent marker pad respectively, Preparing two kinds of fluorescent marker pads, in solution, fluorescent microsphere is 5:1 with the mass ratio of label, and the concentration of solution is 10mg/ml, quantity for spray is 4ul/cm;
2) on the detection line and nature controlling line of nitrocellulose filter, appropriate SLO and sheep anti-mouse antibody solution are sprayed respectively, and Be coated with appropriate people degeneration IgG and sheep anti-mouse antibody solution, prepare two kinds be coated after nitrocellulose filter, the concentration of spray solution For 1mg/ml, quantity for spray is 1ul/cm;
3) nitrocellulose filter, adsorptive pads prepared by the fluorescent marker pad sample pad, step 1 prepared, step 2 depend on Secondary being pasted onto on respective PVC base plate, cutting prepares rheumatoid factor Test paper card and the streptococcus haemolysis of wide 3-5mm Element O Test paper card;Finally Test paper is snapped fits into the prepared detection kit that gets stuck.
Normal line curve:
Respectively by concentration be 0,20,50,100,150,200,250,300,400, the rheumatoid factor of 500ng/mL delays Dissolved drop is added in sample pad, and each concentration sets 5 repetitions (testing result takes 5 meansigma methodss repeated), film chromatography 10 After minute, immunoassay instrument is used to pass through acquisition testing line (T) and nature controlling line (C) band fluorescence signal, analyser Detection range to fluorescence signal is AD value 0-10000, calculates T/C signal value, sets up rheumatoid factor calibration curve, wherein Y-axis is T/C signal value, and X-axis is standard substance actual value.
Respectively by concentration be 0,20,50,100,150,200,250,300,400, the streptococcus haemolysis of 500pg/mL Element O buffer solution drips in sample pad, and each concentration sets 5 repetitions (testing result takes 5 meansigma methodss repeated), film After chromatographing 10 minutes, immunoassay instrument is used to pass through acquisition testing line (T) and nature controlling line (C) band fluorescence signal, Calculating T/C signal value, set up antistreptolysin O (ASO) calibration curve, wherein Y-axis is T/C signal value, and X-axis is standard substance Actual value.
Rheumatoid factor, the detection of antistreptolysin O (ASO) content anti-interference:
Being added in sample pad by detection sample drop, each sample sets 5 repetitions (testing result takes 5 meansigma methodss repeated), film After chromatographing 10 minutes, the T/C value obtained during by detection sample compares with standard curve, it is thus achieved that detect rheumatoid in sample because of Son, the detection data of antistreptolysin O (ASO) content, then rheumatoid factor, the antistreptolysin O (ASO) of detection acquisition are contained Amount data contrast with true rheumatoid factor, antistreptolysin O (ASO) content data, it is thus achieved that accuracy affects deviation value.
Sample 1:50ng/mL rheumatoid factor, 300pg/mL antistreptolysin O (ASO) content, 600mg/L hemoglobin, 100mg/dL triglyceride, 10mg/dL bilirubin;
Sample 2:100ng/mL rheumatoid factor, 200pg/mL antistreptolysin O (ASO) content, 500mg/L hemoglobin, 50mg/dL triglyceride, 15mg/dL bilirubin;
Sample 3:150ng/mL rheumatoid factor, 150pg/mL antistreptolysin O (ASO) content, 80mg/L hemoglobin, 20mg/dL triglyceride, 20mg/dL bilirubin;
Sample 4:200ng/mL rheumatoid factor, 100pg/mL antistreptolysin O (ASO) content, 150mg/L hemoglobin, 30mg/dL triglyceride, 4mg/dL bilirubin;
Sample 5:300ng/mL rheumatoid factor, 50pg/mL antistreptolysin O (ASO) content, 300mg/L hemoglobin, 80mg/dL triglyceride, 9mg/dL bilirubin;
Blank control sample: 300mg/L hemoglobin, 80mg/dL triglyceride, 9mg/dL bilirubin serum sample.
The rheumatoid factor content data of the detection that sample 1-5 is obtained be respectively 48ng/mL, 102ng/mL, 149ng/mL, 198ng/mL, 315ng/mL, antistreptolysin O (ASO) content be respectively 290pg/mL, 202pg/mL, 145pg/mL, 95pg/mL, 52pg/mL, accuracy affect variation < 10%, blank does not finds that obvious fluorescence signal changes.
Embodiment 2
The preparation of comparative example test card: only changing pre-treatment buffer formula, the pre-treatment buffer of comparative example test card is 25mM Glycine buffer, pH=7.4, other steps are all identical with preparation process in embodiment 1.
Rheumatoid factor, the susceptiveness of antistreptolysin O (ASO) and detection limit contrast experiment:
Judging with fluorescent instrument, the detection range to fluorescence signal of analyser is AD value 0-10000, according to the property of instrument Can, CUTOFF value is 50, under certain concentration, and more than 90% detection example AD value >=50, i.e. think that test kit can be used in Detection under this concentration.
Use 5%BSA normal saline solution should not contain measured object as dummy, dummy.Take 0.3-5.3ng/mL ladder The known blood sample of rheumatoid factor of degree concentration carries out susceptiveness detection, arranges a gradient at interval of 0.2ng/mL, and each gradient sets Put 20 samples, record testing result.Result display test card lowest detection prepared by embodiment 1 is limited to 0.5ng/mL, The lowest detectable limit of comparative example test card is higher than 5.3ng/mL.
Use 5%BSA normal saline solution should not contain measured object as dummy, dummy.Take the anti-of 1-50pg/mL The known blood sample of streptolysin O carries out susceptiveness detection, arranges a gradient at interval of 1pg/mL, and each gradient arranges 20 Individual sample, records testing result.Result display test card lowest detection prepared by embodiment 1 is limited to 3pg/mL, and comparative example is tried The lowest detectable limit of paper card is higher than 50pg/mL.
In sum, the present invention effectively overcomes various shortcoming of the prior art and has high industrial utilization.
The principle of above-described embodiment only illustrative present invention and effect thereof, not for limiting the present invention.Any it is familiar with this skill Above-described embodiment all can be modified under the spirit and the scope of the present invention or change by the personage of art.Therefore, such as All that in art, tool usually intellectual is completed under without departing from disclosed spirit and technological thought etc. Effect is modified or changes, and must be contained by the claim of the present invention.

Claims (6)

1. a detection kit for detection by quantitative rheumatoid factor, antistreptolysin O (ASO), including the most independent rheumatoid because of Sub-Test paper card and antistreptolysin O (ASO) Test paper card, described rheumatoid factor Test paper card and streptococcus Hemolysin O Test paper card the most each include base plate and be positioned at backplate surface start, from sample-adding end, the sample that is arranged in order Pad, fluorescent marker pad, nitrocellulose filter and adsorptive pads, the fluorescent labeling of described rheumatoid factor Test paper card Comprise people degeneration IgG on thing pad, the fluorescent marker pad of described antistreptolysin O (ASO) Test paper card wraps Containing hammer bacteriolysin O, described each nitrocellulose filter is coated with detection line and nature controlling line, described fluorescent marker pad On hammer bacteriolysin O and people degeneration IgG use fluorescent microsphere labelling, the detection of described rheumatoid factor Test paper card It is coated with people degeneration IgG on line, the detection line of described antistreptolysin O (ASO) Test paper card is coated with streptococcus haemolysis Element O, described each nature controlling line is coated sheep anti-mouse antibody;
Described each fluorescent marker pad also pre-treatment buffer used in pretreatment, pretreatment includes following group Point: stachyose, Alumen, Fructose Diphosphate sodium, sodium hexameta phosphate and glycine, and stachyose, Alumen, Fructose Diphosphate sodium, Sodium hexameta phosphate, the total concentration of glycine are 3.5-7.5g/L, and the pH value of buffer is 7.2-7.6, and each component is in buffer Concentration be:
The solvent of described pre-treatment buffer is water.
2. detection by quantitative rheumatoid factor, the detection kit of antistreptolysin O (ASO) as claimed in claim 1, its feature exists In, on described each nitrocellulose filter, detection line is positioned at side close to sample-adding end, and nature controlling line is positioned at from sample-adding end farther out Side.
3. detection by quantitative rheumatoid factor, the detection kit of antistreptolysin O (ASO) as claimed in claim 1, its feature exists In, also include getting stuck, described in get stuck and include that back card and upper cover, described back card are provided with two parallel test card draw-in grooves, described Test card is embedded in described test card draw-in groove respectively, described on be covered with two testing windows and two wells, said two is surveyed Match with detection line and the position of nature controlling line of two test cards respectively in the position of examination window, the position of said two well with Match in the position of the sample pad of two test cards.
4. detection by quantitative rheumatoid factor, the detection kit of antistreptolysin O (ASO) as claimed in claim 3, its feature exists In, it is additionally provided with the translot connecting two wells between said two well.
5. detection by quantitative rheumatoid factor, the detection kit of antistreptolysin O (ASO) as claimed in claim 1, its feature exists In, described detection kit detects rheumatoid factor, the content of antistreptolysin O (ASO) for simultaneous quantitative.
6. the preparation method of the detection kit as described in claim 1-5 any claim, comprises the steps:
1) with the streptolysin O of fluorescent microsphere labelling and people's degeneration IgG solution spray respectively antistreptolysin O (ASO), Rheumatoid factor fluorescent marker pad;
2) spray respectively on the detection line and nature controlling line of antistreptolysin O (ASO) nitrocellulose filter streptolysin O and Sheep anti-mouse antibody, sprays people degeneration IgG and sheep anti mouse on the detection line and nature controlling line of rheumatoid factor nitrocellulose filter respectively Antibody;
3) nitrocellulose filter prepared by the fluorescent marker pad two set sample pad, steps 1 prepared, step 2, water suction Pad is pasted onto on respective base plate successively, and cutting prepares Test paper card;Finally being snapped fits into by Test paper gets stuck prepares detection examination Agent box.
CN201410738142.8A 2014-12-05 2014-12-05 A kind of detection by quantitative rheumatoid factor, the detection kit of antistreptolysin O (ASO) Active CN104374911B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410738142.8A CN104374911B (en) 2014-12-05 2014-12-05 A kind of detection by quantitative rheumatoid factor, the detection kit of antistreptolysin O (ASO)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410738142.8A CN104374911B (en) 2014-12-05 2014-12-05 A kind of detection by quantitative rheumatoid factor, the detection kit of antistreptolysin O (ASO)

Publications (2)

Publication Number Publication Date
CN104374911A CN104374911A (en) 2015-02-25
CN104374911B true CN104374911B (en) 2016-08-17

Family

ID=52553956

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410738142.8A Active CN104374911B (en) 2014-12-05 2014-12-05 A kind of detection by quantitative rheumatoid factor, the detection kit of antistreptolysin O (ASO)

Country Status (1)

Country Link
CN (1) CN104374911B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104931706B (en) * 2015-05-02 2017-06-13 王贤俊 A kind of antistreptolysin O detection kit and its preparation
CN112285358A (en) * 2020-09-17 2021-01-29 上海基灵生物科技有限公司 Reagent card for dog C-reactive protein and pancreas specific lipase duplex detection
CN114236135A (en) * 2021-12-15 2022-03-25 上海捷门生物技术有限公司 Test strip for detecting anti-streptolysin O antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102707050A (en) * 2012-05-24 2012-10-03 蓝十字生物药业(北京)有限公司 Colloidal gold test strip for fast detecting rheumatoid factors
CN203732542U (en) * 2013-10-17 2014-07-23 上海科新生物技术股份有限公司 Test paper card and diagnostic kit for detecting rheumatoid arthritis
CN203838159U (en) * 2014-02-26 2014-09-17 郑州浪峰生物技术有限公司 Colloidal gold test paper strip for detecting anti-cyclic citrullinated peptide antibodies and rheumatoid factors

Also Published As

Publication number Publication date
CN104374911A (en) 2015-02-25

Similar Documents

Publication Publication Date Title
CN108279309B (en) Detection test strip and detection method for PLA2R antibody
CN104360085B (en) A kind of AFP detection kit
Koide et al. Determination of human serum 8-hydroxy-2′-deoxyguanosine (8-OHdG) by HPLC-ECD combined with solid phase extraction (SPE)
US20070059682A1 (en) Method to increase specificity and/or accuracy of lateral flow immunoassays
WO2003066906A3 (en) Diagnostic microarray and method of use thereof
CN104374911B (en) A kind of detection by quantitative rheumatoid factor, the detection kit of antistreptolysin O (ASO)
CN104459140B (en) The detection kit of a kind of detection by quantitative Rheumatoid factors, polyclonal, antistreptolysin O, cyclic citrullinated peptid, c reactive protein
CN102841206B (en) TnT (Troponin-T, TNT) measures kit
BR9609771A (en) Process for quantitative measurement of amyloid protein a; recombinant protein; acute phase human serum specific antiserum.
Nelson The use of bioreactive probes in protein characterization
Galbusera et al. Molecular interaction in capillary electrophoresis
CN104937418A (en) Calibrating assays using reaction time
CN105988008B (en) Determine device, kit and method
CN104360083B (en) A kind of detection by quantitative rheumatoid factor, antistreptolysin O (ASO), the detection kit of c reactive protein
Real-Fernández et al. Label-free method for anti-glucopeptide antibody detection in Multiple Sclerosis
CN104459138A (en) Detection kit for insulin-like growth factor binding protein-1
EP3290918A1 (en) Immunochromatography device having reduced background noises, and method for reducing background noises in immunochromatographty device
EP3234194A1 (en) New method for detecting human butyrylcholinesterase
Shaw et al. Determination of sialic acids by liquid chromatography–mass spectrometry
CN104897905B (en) A kind of c reactive protein gold-immunochromatographyreagent reagent for assay box
CN107907694A (en) Anti- mullerian duct hormone test kit and preparation method thereof
CN107402300A (en) A kind of method of quick discriminating human parathyroid
HUP9904222A2 (en) Assay for the detection of antibodies against p53
CN107064492B (en) A kind of fast qualitative quantitative detecting method of oil-adjuvant vaccine
CN104360079A (en) PIVKA-II detection kit

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20180111

Address after: 400000 Taikang Road Dadukou District of Chongqing Bridge Industrial Park C District No. 6 Building 30 layer 1-4

Patentee after: Chongqing Zhongyuan Ji Ji Biological Technology Co., Ltd.

Address before: Jiulongpo Branch Park four street 400039 Chongqing city 70-1, 70-2 block J No. six

Patentee before: CHONGQING QIANDE BIOTECHNOLOGY CO., LTD.

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Floor 1-4, building 30, no.6, Taikang Road, Zone C, Jianqiao Industrial Park, Dadukou District, Chongqing 400000

Patentee after: Zhongyuan Huiji Biotechnology Co.,Ltd.

Address before: Floor 1-4, building 30, no.6, Taikang Road, Zone C, Jianqiao Industrial Park, Dadukou District, Chongqing 400000

Patentee before: CHONGQING ZHONGYUAN HUIJI BIOTECHNOLOGY Co.,Ltd.